Spring Bank Pharmaceuticals, Inc. (AMEX:SBPH) was founded on October 7, 2002, formerly known as Spring Bank Technologies, Inc., changed its current name on May 12, 2008, and was reorganized as a Delaware company at the same time The company, headquartered in Milford, Massachusetts, with 21 full-time employees (12/31/2018), is a clinical-stage biopharmaceutical company that focuses on the use of its proprietary Small Molecule Nucleic-acid Hybrid (SMNH) ) The chemical platform discovers and develops new innovative therapies.
Spring Bank Pharmaceuticals (SBPH):
Spring Bank Pharmaceuticals’ proprietary SMNH compound is a small fragment of nucleic acid designed to selectively and target the activity of specific proteins involved in various disease states to achieve therapeutic effects.
The main product candidate of Spring Bank Pharmaceuticals’ SMNH platform is called SB 9200, which is used for the treatment of viral diseases and can selectively activate host cell proteins (RIG I and NOD 2, which are related to viral infections and immune responses). Inhibit virus replication and induce changes in the signal transduction pathway of intracellular interferon in the antiviral defense system. Therefore, SB9200 can play an important role in treatment by regulating the host’s immune response to combat viral infections.
Spring Bank Pharmaceuticals plans to start two new clinical trials for SB 9200 in 2016:
- Begin treatment of the IIa clinical stage of chronic hepatitis B virus (HBV) without cirrhosis;
- Started the Phase II clinical trial phase for the treatment of Respiratory Syncytial Virus (RSV).
Spring Bank Pharmaceuticals (SBPH) investment:
SBPH submitted its IPO prospectus on January 5, 2016, and was listed on Nasdaq on May 6, 2016 together with Cancer Prevention Pharmaceuticals (CPP), Oncobiologics, Inc. (ONS), and Intellia Therapeutics (NTLA). USD 12.00, issued 900,000 shares, raised USD 11.04 million, stock code: SBPH.